Online inquiry

IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8957MR)

This product GTTS-WQ8957MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL1RL2 gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_001351446.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8808
UniProt ID Q9HB29
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8957MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11970MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ7969MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ6386MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ11481MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ13532MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ3192MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ206MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ6101MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO-1959
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW